| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3978349 | Bulletin du Cancer | 2014 | 9 Pages |
Abstract
The availability of Oncotype DX® in Franche-Comté, France, and its use in clinical routine allowed a decrease of 73 % of adjuvant chemotherapy without increase of the cost of the patients' management and with a potential reduction of the cost for the French Public Healthcare System. This strategy was successful and may allow the reimbursement of this test in France for patients with early breast cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Virginie Nerich, Elsa Curtit, Fernando Bazan, Philippe Montcuquet, Cristian Villanueva, Loïc Chaigneau, Laurent Cals, Nathalie Méneveau, Erion Dobi, Hamadi Altmotlak, Marie-Paule Algros, Marie-Jeanne Choulot, Gilles Nallet, Samuel Limat,